Valganciclovir Shortage Update: What Patients Need to Know in 2026

If you take valganciclovir — whether as Valcyte or the generic — you deserve a clear, honest update on availability. CMV prevention and treatment is not something to guess about. Below is what patients need to know about valganciclovir's availability status heading into 2026.

Current Valganciclovir Availability Status (2026)

As of 2026, valganciclovir is NOT on the FDA's official drug shortage list. The FDA Drug Shortages Database (available at accessdata.fda.gov) tracks medications that cannot meet demand nationally, and valganciclovir does not appear there. Generic valganciclovir is produced by several manufacturers, and overall supply to the U.S. market is stable.

However, patients frequently report difficulty finding it at their local pharmacy. This is not a shortage — it is a distribution and stocking issue driven by the drug's specialty status and high price point.

Why Valganciclovir Can Feel Like It's in Shortage

Valganciclovir belongs to a category called specialty drugs. These medications serve smaller, sicker patient populations — in this case, organ transplant recipients and people with AIDS and CMV complications. Because demand is limited and the drug is expensive (retail cash price can exceed $3,000–$3,400 for a 30-day supply without a coupon), most retail pharmacies simply don't stock it.

When a transplant patient goes home from the hospital and tries to fill valganciclovir at their nearest CVS or Walgreens, they may be told it's "not available" or "needs to be ordered." This can feel alarming — but it usually means the pharmacy doesn't carry it, not that there's none in the country.

Has There Been a Past Valganciclovir Shortage?

Valganciclovir's supply history is relatively stable compared to other specialty drugs. The drug has been on the market since 2001 (FDA approval for Valcyte), and generic versions entered the U.S. market after patent expiration, increasing the number of manufacturers and reducing supply risk. There have been localized stocking issues over the years, but no major FDA-recognized national shortage events have been recorded in recent history.

The greater concern in the CMV antiviral space has been shortages of IV ganciclovir and foscarnet — two IV-only drugs used in hospitalized patients with severe CMV disease. These IV formulations face different supply chain vulnerabilities than the oral valganciclovir tablets.

What Patients Should Watch For

Even without a formal shortage, patients should be aware of these warning signs that access may be tightening:

• Your specialty pharmacy is quoting longer lead times (more than 3–4 business days to ship)
• Your pharmacy mentions being "on allocation" — meaning their wholesaler is limiting quantities
• Your price has suddenly spiked significantly beyond the usual coupon range
• Multiple pharmacies in a row cannot fill the prescription within 48 hours

If any of these occur, check the FDA Drug Shortages Database at accessdata.fda.gov/scripts/drugshortages and contact your transplant coordinator or infectious disease physician immediately.

How to Protect Your Supply

The best defense against any future supply disruptions is to fill your prescriptions through a reliable specialty pharmacy channel. Here's what to do:

1. Use your transplant center's preferred specialty pharmacy for all refills.
2. Request 90-day supplies when your insurance allows — this reduces the frequency of refill bottlenecks.
3. Refill when you have 10–14 days left, not when you're out.
4. Keep your transplant coordinator informed if you're having any trouble filling.

Can't Find Valganciclovir Right Now? Here's Help

If you are struggling to find valganciclovir at a pharmacy near you, medfinder contacts local pharmacies on your behalf to find out which ones can fill your prescription. You provide your medication details and location — medfinder calls the pharmacies and texts you the results.

For more step-by-step guidance, see: How to Find Valganciclovir in Stock Near You.